In this issue of Molecular Pharmacology, Kundakovic et al. (p. 644) present compelling evidence suggesting that the promoters for reelin and GAD67 are coordinately regulated. The regulation occurs at the level of DNA (cytosine-5) methylation. Moreover, the authors present evidence suggesting that pharmacologic inhibition of DNA methyltransferase results in reversal of methylation, loss of methyl-DNA binding proteins and relief of repression. Repression of both reelin and GAD67 has been implicated in the pathogenesis of schizophrenia. Therefore, these results suggest that the reelin and GAD67 promoters are subject to continuous repression by DNA methyltransferase and that inhibitors of DNA methyltransferase represent a potential treatment for Schizophrenia.
Schizophrenia is a debilitating neurological disease that afflicts approximately 1% of Americans. The symptoms of schizophrenia are severe and include auditory hallucinations, generalized paranoia, and severe cognitive dysfunction. Because of these phenomena, patients with schizophrenia are unable to function in normal social situations and tend to be fearful, withdrawn, and exhibit disorganized thought and speech. Onset of schizophrenia occurs in late adolescence or early adulthood and is often associated with a precipitating stressful life event. Contemporary treatments relieve some symptoms; however, most persons with schizophrenia continue to experience symptoms throughout their lives.
The nature of schizophrenia suggests that the initial triggering event results in a robust set of neuroadaptations that significantly derange normal brain function. How then, could one event result in widespread maladaptive changes in neural function that last a lifetime? Given that the entire composition of the human brain turns over every 2 months, the triggering event must impinge upon a process that is stable or is perpetuated throughout the lifetime of an individual.
DNA is perhaps the only molecular component of neurons that is not continuously degraded and resynthesized, and represents a unique and powerful substrate for storage of cellular information.
DNA exists in the nucleus as a highly compressed protein-DNA complex known as chromatin. In addition to compressing DNA into the nucleus, chromatin acts as a molecular platform for signal integration and long-term information storage (Levenson and Sweatt, 2005) . For example, every cell in a metazoan must "remember" its phenotype. This information is stored in the cell in the form of stable marks applied directly to chromatin that result in permanent changes to chromatin structure, gene expression, and cellular physiology.
The process of marking DNA and its associated proteins is commonly referred to as epigenetics. Epigenetics has various meanings depending on the context that is used. The broadest definition of epigenetics refers to processes of transmission and perpetuation of information through mitosis or meiosis that do not rely on DNA sequence. In this context, epigenetics encompasses DNA, RNA, and protein-based mechanisms. As applied to the adult nervous system, epigenetics refers to a mechanism for stable maintenance of gene expression whereby the DNA or its associated proteins are physically marked. These marks come in a variety of forms (for review, see Levenson and Sweatt, 2005) . Methylation of cytosine residues is an epigenetic mark applied directly to DNA. Methylation of a cytosine can occur only when it exists as a cytosine-guanine dinucleotide (CpG). Methylated CpG dinucleotides are bound by methyl-DNA binding proteins, which recruit chromatin-remodeling enzymes, such as histone deacetylases, and actively repress gene expression. DNA methylation is an enzymatic process governed by DNA methyltransferase and an as-yet-unidentified DNA methylase.
An increasing body of literature indicates that the adult nervous system uses epigenetic marks to chromatin for integration and storage of information. Moreover, there are several examples whereby a single, precipitating event in the lifetime of an organism results in an epigenetic mark to chromatin, lasting changes in expression of one or more genes, and lifetime changes in behavior (Weaver et al., 2004; Kumar et al., 2005; Champagne et al., 2006) . Given the sudden onset and lifetime persistence of symptoms, it is reasonable to hypothesize that the pathogenesis of schizophrenia is due, at least in part, to aberrant epigenetic marking of one or more genes, resulting in lifetime changes in their expression.
Postmortem studies of gene expression in the brains from persons diagnosed with schizophrenia have revealed that expression of glutamic acid decarboxylase 67 (GAD67), an enzyme critical for synthesis of the inhibitory neurotransmitter GABA, is significantly reduced in interneurons. Moreover, expression of reelin, an extracellular matrix-associated protein important for development and cognitive function (Weeber et al., 2002; Qiu et al., 2006) , is also significantly reduced in these same neurons. Animal models of reelin haploinsufficiency exhibit reduced GABAergic inhibitory tone and a deficit in sensorimotor gating, hallmarks of schizophrenia (Tueting et al., 1999; Qiu et al., 2006) . As a whole, these results suggest that an aberrant decrease in reelin and GAD67 gene expression could contribute to the pathogenesis of schizophrenia.
In this issue of Molecular Pharmacology, Kundakovic et al. (2007) explore the hypothesis that methylation of the proximal promoters of reelin and GAD67 are coregulated and, if so, whether the methylation status could be manipulated using DNA (cytosine-5) methyltransferase (DNMT) inhibitors. Previous studies have demonstrated that a CpG island exists in the proximal promoter of reelin (Chen et al., 2002) . CpG islands are regions in the genome in which CpG dinucleotides occur at a frequency greater than would normally be expected. It is noteworthy that although CpG islands in general are usually hypomethylated, postmortem studies suggest that the reelin promoter is actually hypermethylated in persons with schizophrenia (Chen et al., 2002; Abdolmaleky et al., 2005) . This hypermethylation could explain the reduction in reelin expression associated with schizophrenia. Kundakovic et al. (2007) postulate that this hypermethylation could also serve as a basis for therapeutic intervention. Kundakovic et al. (2007) exploited NT-2 neuronal progenitor cells to study the regulation of reelin expression. NT-2 cells are ideal for these studies because they exhibit low levels of reelin expression and hypermethylation of the reelin promoter (Chen et al., 2002) , modeling some of the molecular derangements associated with schizophrenia. Long-term treatment of NT-2 cells with the DNMT inhibitor doxorubicin significantly increased expression of reelin and GAD67. It is surprising that the increase in reelin and GAD67 was preceded by a significant decrease in expression of DNMT1 protein. Further studies revealed that doxorubicin decreased levels of DNMT1 and the methyl-DNA binding protein MeCP2 and increased levels of histone acetylation at the reelin promoter. These results suggest that in NT-2 cells, at least, the reelin promoter is actively repressed through the action of DNMT, and this repression is mediated via MeCP2dependent chromatin remodeling (Fig. 1A) . Furthermore, these results support other findings suggesting that DNMT inhibitors may block DNMT activity by promoting degradation of DNMT (Fig. 1B) , perhaps through formation of nonfunctional complexes (Yokochi and Robertson, 2004) .
The findings of Kundakovic et al. (2007) are striking when one considers the ramifications for intervention in schizophrenia. Hypermethylation of the reelin and GAD67 promoters, whether due to a triggering event during development or during adolescence, represents an epigenetic 
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Levenson mark that persists for a person's lifetime. However, the use of DNMT inhibitors to treat schizophrenia or any disease is years away at best, because drugs of this nature will probably result in up-regulation of numerous genes that are actively repressed via DNMT. Despite the potential drawbacks, the ability to pharmacologically erase an epigenetic mark with DNMT inhibitors and reverse some or all of the derangements in brain function associated with schizophrenia is revolutionary.
